Pegylated Interferon-α2b plus Ribavirin: An Efficacious and well-Tolerated Treatment Regimen for Patients with Hepatitis C virus Related Histologically Proven CirrhosisLuigi Roff, Savino Bruno, Angelo Rossini et al.|Antiviral Therapy|2008Cited by 33
755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICSPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2013Cited by 24
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDYPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2012Cited by 10
OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCEPietro Lampertico, C Massimo, Mauro Viganò et al.|Digestive and Liver Disease|2011Cited by 8
Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter studyPietro Lampertico, Massimo Colombo, Mauro Viganò et al.|F1000Research|2012Cited by 3